K. Tourian

发表

Rita Ganguly, Michael R. Liebowitz, Amy L. Manley, 2008 .

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.

M. Liebowitz, S. K. Padmanabhan, R. Tummala, 2008, Current medical research and opinion.

A Randomized Controlled Trial of Venlafaxine ER Versus Placebo in Pediatric Social Anxiety Disorder

Moira Rynn, Anne Marie Albano, John S. March, 2007, Biological Psychiatry.

Validity of three measures of antisociality in predicting HIV risk behaviors in methadone-maintenance patients.

J. McKay, D. Metzger, A. Alterman, 1997, Drug and alcohol dependence.

Baseline prediction of 7-month cocaine abstinence for cocaine dependence patients.

J. McKay, A. Cnaan, A. Alterman, 2000, Drug and alcohol dependence.

An Evaluation of the Efficacy, Safety, and Tolerability of Desvenlafaxine in the Long-term Treatment of Elderly Outpatients With Major Depressive Disorder

S. K. Padmanabhan, A. Nichols, J. Ferguson, 2010 .

Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial.

P. Boyer, J. Rosenthal, E. Hwang, 2013, Journal of Clinical Psychiatry.

Desvenlafaxine for the Prevention of Relapse in Major Depressive Disorder: Results of a Randomized Trial

J. Guelfi, S. Montgomery, K. Rickels, 2010, Journal of clinical psychopharmacology.

Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis

S. Kornstein, A. Clayton, L. Abraham, 2015, International clinical psychopharmacology.

Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis

M. Thase, J. Sporn, R. Fayyad, 2015, Current medical research and opinion.

Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder.

R. Findling, J. Groark, Sara Ramaker, 2014, Journal of child and adolescent psychopharmacology.

Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder

M. Fava, S. Montgomery, S. K. Padmanabhan, 2009, International clinical psychopharmacology.

Analysis of the Effect of Desvenlafaxine on Anxiety Symptoms Associated with Major Depressive Disorder: Pooled Data from 9 Short-Term, Double-blind, Placebo-Controlled Trials

P. Ninan, K. Tourian, Q. Jiang, 2010, CNS Spectrums.

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

M. Liebowitz, E. Hwang, K. Tourian, 2013, BMC Psychiatry.

Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.

M. Liebowitz, K. Tourian, 2010, Primary care companion to the Journal of clinical psychiatry.

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.

S. K. Padmanabhan, J. Groark, K. Tourian, 2009, Clinical therapeutics.

Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial.

M. Thase, A. Clayton, E. Hwang, 2014, The Journal of clinical psychiatry.

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

S. Montgomery, U. Lepola, P. Boyer, 2008, International clinical psychopharmacology.

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder*

M. Liebowitz, S. K. Padmanabhan, R. Tummala, 2008 .

A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence.

C. O'brien, C. Dackis, J. Cornish, 2003, Addictive behaviors.

A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlafaxine Treatment in Outpatients with Major Depressive Disorder

S. K. Padmanabhan, A. Feiger, K. Tourian, 2009, CNS Spectrums.

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder

S. Montgomery, Krishnan Padmanabhan, B. Pitrosky, 2008, International clinical psychopharmacology.

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder

B. Pitrosky, S. K. Padmanabhan, J. Germain, 2007, International clinical psychopharmacology.

Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.

R. Findling, J. Groark, Sara Ramaker, 2016, Journal of child and adolescent psychopharmacology.

A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder.

B. Pitrosky, S. K. Padmanabhan, K. Tourian, 2011, The primary care companion for CNS disorders.

Desvenlafaxine and weight change in major depressive disorder.

P. Ninan, J. Graepel, K. Tourian, 2010, Primary care companion to the Journal of clinical psychiatry.

Efficacy and Safety of Desvenlafaxine 25 and 50 Mg/Day in a Randomized, Placebo-Controlled Study of Depressed Outpatients

N. Iwata, E. Hwang, K. Tourian, 2013, Journal of psychiatric practice.

Retrospective Analysis of Suicidality in Patients Treated With the Antidepressant Desvenlafaxine

P. Ninan, Krishnan Padmanabhan, J. Groark, 2010, Journal of clinical psychopharmacology.

An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder

S. Kornstein, A. Clayton, C. Guico-Pabia, 2009, CNS Spectrums.

P0031 - Pooled analysis of the safety and tolerability of desvenlafaxine Succinate compared with placebo in the treatment of major depressive disorder

S. Kornstein, A. Clayton, L. Lamm, 2008, European Psychiatry.

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor

J. Paul, Susanna Tse, Alice I Nichols, 2010, Expert opinion on drug metabolism & toxicology.

High-dose desvenlafaxine in outpatients with major depressive disorder

J. Ferguson, K. Tourian, G. Rosas, 2012, CNS Spectrums.

HAM-D17 and HAM-D6 Sensitivity to Change in Relation to Desvenlafaxine Dose and Baseline Depression Severity in Major Depressive Disorder

P. Bech, P. Boyer, B. Pitrosky, 2010, Pharmacopsychiatry.

Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial.

P. Boyer, E. Hwang, K. Tourian, 2015, The primary care companion for CNS disorders.

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor

J. Paul, Susanna Tse, A. Nichols, 2010, Expert opinion on drug metabolism & toxicology.